untitled h1
references references in introduction pancreatic

American Cancer Society.: Cancer Facts and Figures 2009. Atlanta, Ga: American Cancer Society, 2009. Greenlee RT, Murray T, Bolden S, et al.: Cancer statistics, 2000. CA Cancer J Clin 50 (1): 7-33, 2000 Jan-Feb Yeo CJ, Abrams RA, Grochow LB, et al.: Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg 225 (5): 621-33; discussion 633-6, 1997. Lillemoe KD: Current management of pancreatic carcinoma. Ann Surg 221 (2): 133-48, 1995. Yeo CJ: Pancreatic cancer: 1998 update. J Am Coll Surg 187 (4): 429-42, 1998. Nitecki SS, Sarr MG, Colby TV, et al.: Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving? Ann Surg 221 (1): 59-66, 1995. [• Conlon KC, Klimstra DS, Brennan MF: Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5year survivors. Ann Surg 223 (3): 273-9, 1996. [ Willett CG, Daly WJ, Warshaw AL: CA 19-9 is an index of response to neoadjunctive chemoradiation therapy in pancreatic cancer. Am J Surg 172 (4): 350-2, 1996. Norton, L, Simon, R., Bereton, H.D., Bogden, A.E. Predicting the course of Gompertzian growth. Nature 264: 542-45. 1976. Norton, L. A Gompertzian model of human breast cancer growth. Cancer Res 48; 7067-71. 1988. Norton, L. Cancer stem cells, self-seeding, and decremented exponential growth: Theoretical and clinical implications. Breast Dis 29: 27-36. 2008. Speer, J.F., Petrosky, V.E., Retsky, M.W., Wardwell, R.H. A stochastic numerical model of breast cancer growth that simulates clinical data. Cancer Res 44:412430. 1984. Laird, A.K. Dynamics of tumor growth: Comparison of growth rates and extrapolation of growth curve to one cell. *Brit J Cancer* 29:278-291. 1965. Laird, A.K., Tyler, S.A., Barton, A.D. Dynamics of normal growth. *Growth* 29: 233248. 1965. De Wys, WD. Studies correlating the growth rate of a tumor and its metastases and providing evidence for tumor-related systemic growth-retarding factors. Cancer Res 32(2): 374-9, 1972. Fisher, B. et al. Presence of a growth-stimulating factor in serum following primary tumor removal in mice. Cancer Res 49(8): 1996-2001, 1989.
untitled h1
colorectal cancer

Gleisner, A.L., Choti, M.A., Assumpcao, L., Nathan, H. Schulick, RD, Pawlik, T.M. Colorectal liver metastases: recurrence and survival following hepatic resection, radiofrequency ablation, and combined resection-radiofrequency ablation. Arch Surg 143(12):1204-12. 2008. Ocean AJ, Parikh T, Berman N, Escalon J, Shah MA, Andrada Z. Phase I/II trial of intraperitoneal implantation of agarose-agarose macrobeads (MB) containing mouse renal adenocarcinoma cells (RENCA) in patients (pts) with advanced colorectal cancer (CRC). American Society of Clinical Oncology (ASCO) Annual 2013 Meeting, Chicago IL (Abstract). Onaitis, M.W., Peterson, RP, Haney, J.C., Saltz, L. Park, B. Flores, R., Bains, M.S. Dycoco J., D'Amico, T.A., Harpole, D.H., Kemeny, N., Rusch, V.W., Downey, R. Prognostic factors after pulmonary resection of colorectal cancer metastases. Ann Thorac. Surg 87(6): 1684-8. 2009. Timmerman, R.D., Bizekis, C.S., Pass, H.I., Fong, Y., Dupuy, D.E., Dawson, L.A., Lu, D. Local surgical, ablative, and radiation treatment of metastases. CA Cancer J Clin 59(3):145-170. 2009. (Epub, April 2009). Wolpin, B.M., Mayer, R.J. Systemic treatment of colorectal cancer. Gastroenterology 134(5): 2008 1296-1310. 2008. Yamane, B., Weber, S. Liver-directed treatment modalities for primary and secondary hepatic tumors. Surg Clin N Amer 89(1):97-113.
untitled h1
cancer general references

Al-Hajj, M. et al, Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100(7): 3983-8, 2003. Clark, MF, Fuller, M. Stem cells and cancer: Two faces of Eve. Cell 124: 11111115, 2006. Fan, X, Matsui, W, Khaki, L, et al. Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res 66:7445-7452, 2007. Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A, on behalf of the EORTC Quality of Life Group. The EORTC QLQ-C30 Scoring Manual (3rd Edition). Published by: European Organisation for Research and Treatment of Cancer, Brussels 2001. Gazda LS, Martis PC, Laramore MA, Bautista MA, Dudley A, Vinerean HV, Smith BH. Treatment of agarose-agarose RENCA macrobeads with docetaxel selects for OCT4+ cells with tumor-initiating capability. Cancer Biology & Therapy December 2013; 14:12, Gilbertson, RJ, Rich, JN. Making a tumour's bed: Glioblastoma stem cells and the vascular niche. Nat Rev Cancer 7:733-736, 2007. Hanahan, D, Weinberg, RA. The hallmarks of cancer. Cell 100: 57-70, 2000. Karnofsky DA, Burchenal JH. The Clinical Evaluation of Chemotherapeutic Agents in Cancer. In: MacLeod CM (Ed), Evaluation of Chemotherapeutic Agents. Columbia Univ Press 1949. page 196. Keir CH, Ocean AJ, Fahey TJ, Berman N, Wadke A, Kelly-Rossini L, Goldstein MJ, Leeser DB, Michelassi F, Smith BH. Treatment of advanced, epithelial-derived cancer (AEC) with intraperitoneal implantation of agarose-agarose macrobeads (MB) containing mouse renal adenocarcinoma cells (RENCA). American Society of Clinical Oncology (ASCO) Annual 2011 Meeting; J Clin Oncol 29: 2011 (suppl; abstr e13594). Kobielak, K, Stokes, N, de la Cruz, J et al. Loss of a quiescent niche but not follicle stem cells in the absence of bone morphogenic protein signaling. Proc Nat Acad Sci USA 104: 10062-10068, 2007 Littlepage, LE, Egeblad, M, Werb, Z. Coevolution of cancer and stromal cellular responses. Cancer Cell 7:499-500, 2007. Matsushansky, I Hernando, E, Socci, N, et al. Derivation of sarcomas from mesenchymal stem cells via inactivation of the Wnt pathway. J Clin Invest 117: 3248-3257, 2007. Moore KA, Lemischka, IR. Stem cells and their niches. Science 311: 1880-1885, 2006. Prehn, RT. The inhibition of tumor growth by tumor mass. Cancer Res 51(1): 2-4, 1991. Reya, T. et al. Stem cells, cancer, and cancer stem cells. Nature 414(6859): 10511, 2001. Sanai, N, Alvarez-Buylla, A, Berger,MS. Neural stem cells and the origins of gliomas. N Engl J Med 353: 811-822, 2005. Smith, BH. et al, Feedback inhibition in the regulation of malignant cell proliferation and tumor growth: the agarose-agarose mouse renal adenocarcinoma cancer macrobead. Manuscript to be submitted to Nature Oncology, 2008. Smith BH, Gazda LS, Conn BL, Jain K, Asina S, Levine DM, et al. Hydrophilic agarose macrobead cultures select outgrowth of carcinoma cell populations that can restrict cancer growth. Cancer Res 2011;71(3):725-35. (a) Smith BH, Gazda LS, Conn BL, et al. Three-dimensional culture of mouse renal carcinoma cells in agarose macrobeads selects for a subpopulation of cells with cancer stem cell or cancer progenitor properties. Cancer Res. 2011;71(3):716724. (b) Sneddon, JB, Werb, Z. Location, location, location: The cancer stem cell niche. Cell Stem Cell 1:607-611, 2007. Tu, SM et al. Stem-cell origin of metastasis and heterogeneity in solid tumors. Lancet Oncol 3(8): 508-13, 2002
untitled h1
xenotransplantation

Bach, FH. Xenotransplantation: problems and prospects. Ann Rev Med 49: 301310, 1998. Boneva, RS, Folks, TM, Chapman, LE. Infectious disease issues in xenotransplantation. Clinical Microbiol Rev. 14: 1-14. 2001. Chapman, LE, Folks, T, Salomon, D, et al. Xenotransplantation xenogenic infections. NEJM 333: 1498-1500. 1995. Denner, J. Is porcine endogenous retrovirus transmission still relevant? Transplant Proc 40:587-589, 2008. Fishman, J, Sachs, D, and Shaikh, R (Eds). Xenotransplantation: Scientific Frontiers and Public Policy. Ann NY Acad Sci 862: 1, 1998. Fujimura, T, Miyagawa, S, Takahagi, Y, et al. Prevalence of porcine endogenous retroviruses in domestic, miniature, and genetically modified pigs in Japan. Transplant Proc 40:594-595, 2008. Garkavenko, O, Wynyard, S, Nathu, D, et al. Porcine endogenous retrovirus transmission characteristics from a designated pathogen-free herd. Transplant Proc. 40:590-593, 2008. Institute of Medicine. Xenotransplantation: Science, ethics, and public policy. Washington, DC. National Academy Press, 1996. Lower, R, Lower, J and Kurth, R. The viruses in all of us: characteristics and biological significance of human endogenous retrovirus sequences. Proc Nat Acad Sci 93: 5177-5184. 1996. Mattiuzzo, G, Scobie, L, Takeuchi, Y. Strategies to enhance the safety profile of xenotransplantation: minimizing the risk of viral zoonoses. Curr Opin Organ Transplant 13:184-188, 2008. Platt, JL and Nagayasu, T. Current status of xenotransplantation. Clin Exp Pharm Physiol 26: 1026-1032, 1999. Soin, B, Vial, CM, and Friend, PJ. Xenotransplantation. British J. Surg 87:138148, 2000. Weiss, RA. Xenografts and retroviruses. Science 285: 1221, 1999. Weiss, RA. Xenotransplantation: Pausing to reflect. Hospital Practice, (October 15): 71-78, 2000
untitled h1
murine leukemia virus

National Research Council, Companion Guide to Infectious Diseases of Mice and Rats, National Academy Press, Washington, DC, 1991. Charles River Laboratories, Testing for Xenotropic and Non-Xenotropic Murine Leukemia Virus. Protocols GP-600 and GP-V601.1 in accord with GLP regulations, Title 21 CFR Section 58. Ganguly, K, Kalyanaraman, VS, Sarngadharan, MG. Cell surface receptors for ecotropic murine viruses are different from those for xenotropic and amphotropic viruses. Intervirology 19: 224-229. 1983.